New Barcoding System Reveals Why Most Gene Therapies Get Trashed Inside Cells

Published in Nature Biotechnology. Research led by Gaurav Sahay, Oregon State University College of Pharmacy.

Why do most gene therapies fail to deliver? Not because the genetic cargo is flawed, or because the nanoparticles carrying it cannot enter cells. The problem is what happens next. Once inside, the therapeutic payload is frequently routed to lysosomes -- the cell's disposal units -- where it is broken down before it can do its job. The cargo arrives at the building but gets thrown in the dumpster.

The frustrating part, until now, has been the inability to measure this process in living organisms. Researchers could tell that gene therapies worked poorly, but they could not quantify exactly how much cargo was being wasted versus how much reached its target. Without that measurement, improving delivery was largely guesswork.

A study published in Nature Biotechnology, led by graduate student Antony Jozic and professor Gaurav Sahay at Oregon State University's College of Pharmacy, has solved that measurement problem -- and the results are already reshaping how lipid nanoparticles are designed.

Tracking cargo inside the cell

The team developed a DNA-based barcoding test that can distinguish, in mouse models, how much of the genetic material carried by lipid nanoparticles ends up as cellular waste versus how much successfully escapes the lysosome and reaches its intended destination. Each nanoparticle design carries a unique DNA barcode, allowing the researchers to screen many designs simultaneously and compare their intracellular fates.

Sahay framed the significance simply: once you can measure something, you can design around it. The barcoding system transformed what had been an opaque process into a quantifiable one, enabling the team to systematically identify which nanoparticle features promote successful cargo delivery and which do not.

Jozic described the outcome as particularly meaningful after several years of work on the project. The system allowed the team to quantify how efficiently different nanoparticle designs release their cargo -- a capability that did not previously exist for living organisms.

A new class of delivery vehicles

Guided by the measurements from the barcoding system, the researchers identified and validated a new class of lipid nanoparticles built around improved ionizable lipid systems. Ionizable lipids are a key component of nanoparticle design -- they change their electrical charge depending on the acidity of their surroundings, which helps both in packaging genetic material and in interacting with cellular membranes.

The new particles achieved powerful gene editing at much lower doses than current advanced delivery methods. In practical terms, this means less material needs to enter the body to achieve the same therapeutic effect, which reduces off-target effects and improves the safety margin.

The ionizable lipids were developed in collaboration with Paul-Alain Jaffres and his graduate student Chloe Le Roux at the University of Brest in France, along with researchers at OHSU, Tennessee Technological University, and Yeungnam University in South Korea. The collaboration produced some of the most potent ionizable lipids reported to date for delivering gene-editing tools.

Resolving a longstanding debate

Beyond the practical applications, the study addressed a fundamental question in the field: what is the main bottleneck for gene therapy delivery? There had been competing hypotheses -- some researchers argued the primary challenge was getting nanoparticles into cells, while others pointed to the problem of cargo escaping the endosomal-lysosomal pathway once inside.

The barcoding data resolved this debate clearly. The main problem is intracellular trafficking -- getting the cargo to the right compartment within the cell after it has already entered. Many nanoparticle designs are reasonably good at crossing the cell membrane but poor at avoiding the lysosomal disposal route.

Sahay described this insight as resolving a longstanding challenge in the field, noting that the ability to track genetic material inside subcellular compartments within a living organism provides a road map for improving RNA and gene-editing medicines.

What the study does not address

The barcoding system has been demonstrated in mouse models, and translation to humans remains uncertain. Intracellular trafficking can differ between species, and nanoparticle designs optimized for mouse cells may not perform identically in human cells.

The study focused on liver delivery, which is the most accessible organ for lipid nanoparticle-based therapies. Whether the same barcoding approach and the new ionizable lipids can be applied to harder-to-reach tissues -- the brain, lungs, or specific tumor types -- has not been established.

Long-term safety data for the new nanoparticle class are not yet available. While the lower dosing requirements are promising from a safety perspective, comprehensive toxicology studies in larger animal models and eventually humans will be needed before clinical application.

The manufacturing scalability of the new ionizable lipids is also untested at commercial scale. Laboratory synthesis and industrial production often present different challenges, and the economic viability of the new formulations remains to be demonstrated.

From measurement to medicine

The broader impact of the barcoding system may extend well beyond the specific nanoparticles described in this study. By providing a general-purpose tool for measuring intracellular delivery efficiency, the system could accelerate development across the entire gene therapy field -- including CRISPR-based gene editing, RNA interference therapeutics, and mRNA medicines beyond vaccines.

The gene therapy market has grown rapidly in recent years, but delivery remains its central unsolved problem. Most approved gene therapies use viral vectors, which carry their own limitations in terms of immune responses, manufacturing complexity, and cargo capacity. Lipid nanoparticles offer a non-viral alternative, but their clinical utility has been constrained by the very inefficiency that this study now quantifies and addresses.

The research was supported by the National Institutes of Health, the Defense Advanced Research Projects Agency, and the M.J. Murdock Charitable Trust.